Join to View Full Profile
333 Cedar StYale University School Of MedicineNew Haven, CT 06510
Phone+1 203-200-4822
Fax+1 203-200-2099
Dr. Hurwitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2000
Weill Cornell MedicineClass of 1998
Certifications & Licensure
CT State Medical License 2010 - 2026
MA State Medical License 2000 - 2010
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Start of enrollment: 2018 Feb 06
- Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer Start of enrollment: 2019 Dec 23
Roles: Contact, Principal Investigator
- A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Start of enrollment: 2018 Jun 19
Roles: Contact
Publications & Presentations
PubMed
- 1 citationsSurvival of patients with metastatic renal cell carcinoma with or without brain metastases.Noam Savion-Gaiger, Bryden Considine, Nitzan Hasson, Melanie Nelson, Veronica Chiang
The Oncologist. 2025-12-01 - 1 citationsFactors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.Lilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, Jacqueline E Mann, Madeline Candelas Torres
Journal for Immunotherapy of Cancer. 2025-09-10 - Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.Hannah D McManus, Jessica B Long, Sarah J Westvold, Michael S Leapman, Michael E Hurwitz
Clinical Genitourinary Cancer. 2025-06-01
Press Mentions
CAR T Cell Therapy May Eliminate Tumor Cells Missed by SurgeryFebruary 9th, 2023
Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers SymposiumFebruary 19th, 2017- 'We're Not There yet': CAR T-cell Therapy for Renal Cell CarcinomaNovember 17th, 2023
Grant Support
- Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell ReprogrammingYALE UNIVERSITY2023–2025
- Screening Of Synthetic Lethality With C. Elegans RBNational Cancer Institute2004–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
